CBIO Q4 2023 Earnings — Crescent Biopharma, Inc. Revenue & Financial Results | Market Cap Arena

CBIOCrescent Biopharma, Inc.

$345M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$10,000+113.3% YoY

Gross Profit

$10,000100.0% margin

Operating Income

-$10M-95908.3% margin

Net Income

-$9M-90786.4% margin

EPS (Diluted)

$-0.14

QoQ Revenue Growth

+Infinity%

Cash Flow

Operating Cash Flow

-$8M

Free Cash Flow

-$8M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$45M

Total Liabilities

$7M

Stockholders' Equity

$38M

Cash & Equivalents

$42M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$10,000	-$75,000	+113.3%
Gross Profit	$10,000	-$75,000	+113.3%
Operating Income	-$10M	-$11M	+9.7%
Net Income	-$9M	-$10M	+11.4%